| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England journal of medicine 359 (4), 378-390, 2008 | 14897 | 2008 |
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors E Raymond, L Dahan, JL Raoul, YJ Bang, I Borbath, C Lombard-Bohas, ... New England Journal of Medicine 364 (6), 501-513, 2011 | 2938 | 2011 |
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2108 | 2018 |
| Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib … P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ... Jama 315 (17), 1844-1853, 2016 | 1022 | 2016 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276, 2018 | 672 | 2018 |
| Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study A Santoro, L Rimassa, I Borbath, B Daniele, S Salvagni, JL Van Laethem, ... The lancet oncology 14 (1), 55-63, 2013 | 656 | 2013 |
| Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JW Valle, I Borbath, SA Khan, F Huguet, T Gruenberger, D Arnold Annals of Oncology 27, v28-v37, 2016 | 653 | 2016 |
| Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms M Heetfeld, CN Chougnet, IH Olsen, A Rinke, I Borbath, G Crespo, ... Endocrine-related cancer 22 (4), 657-664, 2015 | 403 | 2015 |
| Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial RK Kelley, L Rimassa, AL Cheng, A Kaseb, S Qin, AX Zhu, SL Chan, ... The Lancet Oncology 23 (8), 995-1008, 2022 | 286 | 2022 |
| ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues RJ Hicks, DJ Kwekkeboom, E Krenning, L Bodei, S Grozinsky-Glasberg, ... Neuroendocrinology 105 (3), 295-309, 2017 | 281 | 2017 |
| Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre … M Javle, S Roychowdhury, RK Kelley, S Sadeghi, T Macarulla, KH Weiss, ... The Lancet Gastroenterology & Hepatology 6 (10), 803-815, 2021 | 263 | 2021 |
| ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology-diagnosis and prognostic stratification A Perren, A Couvelard, JY Scoazec, F Costa, I Borbath, G Delle Fave, ... Neuroendocrinology 105 (3), 196-200, 2017 | 225 | 2017 |
| An update on treatment options for pancreatic adenocarcinoma A Lambert, L Schwarz, I Borbath, A Henry, JL Van Laethem, D Malka, ... Therapeutic advances in medical oncology 11, 1758835919875568, 2019 | 221 | 2019 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 214 | 2023 |
| Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study S Faivre, P Niccoli, D Castellano, JW Valle, P Hammel, JL Raoul, A Vinik, ... Annals of oncology 28 (2), 339-343, 2017 | 202 | 2017 |
| Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or … P Hammel, F Huguet, JL Van Laethem, D Goldstein, B Glimelius, P Artru, ... Journal of Clinical Oncology 31 (15_suppl), LBA4003-LBA4003, 2013 | 202* | 2013 |
| Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline PH Deprez, LMG Moons, D OʼToole, R Gincul, A Seicean, ... Endoscopy 54 (04), 412-429, 2022 | 151 | 2022 |
| Pancreatic neuroendocrine tumour grading on endoscopic ultrasound‐guided fine needle aspiration: high reproducibility and inter‐observer agreement of the K i‐67 labelling index B Weynand, I Borbath, V Bernard, C Sempoux, JF Gigot, C Hubert, ... Cytopathology 25 (6), 389-395, 2014 | 123 | 2014 |
| Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction M Lonneux, I Borbath, A Bol, A Coppens, M Sibomana, R Bausart, ... European journal of nuclear medicine 26, 591-598, 1999 | 118 | 1999 |
| A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic … MH Kulke, P Ruszniewski, E Van Cutsem, C Lombard-Bohas, JW Valle, ... Annals of Oncology 28 (6), 1309-1315, 2017 | 113 | 2017 |
